Clinical Trials Browser

Terminated × Triple Negative Breast Neoplasms × pertuzumab × Clear all

NCT05180006 2025-12-01

BIS-Program

Phase 2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms